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Epigenetic Regulation of the Electrophysiological
Phenotype of Human Embryonic Stem Cell-Derived
Ventricular Cardiomyocytes:
Insights for Driven Maturation and Hypertrophic Growth
Maggie Zi Ying Chow,1,2 Lin Geng,2 Chi-Wing Kong,1,2 Wendy Keung,1,2
Jacky Chun-Kit Fung,2 Kenneth R. Boheler,1,3 and Ronald A. Li1,2,4
Epigenetic regulation is implicated in embryonic development and the control of gene expression in a cell-
specific manner. However, little is known about the role of histone methylation changes on human cardiac
differentiation and maturation. Using human embryonic stem cells (hESCs) and their derived ventricular (V)
cardiomyocytes (CMs) as a model, we examined trimethylation of histone H3 lysine 4 (H3K4me3) and lysine 27
(H3K27me3) on promoters of genes associated with cardiac electrophysiology, contraction, and Ca2 + handling.
To avoid ambiguities due to heterogeneous chamber-specific types, hESC-derived ventricular cardiomyocytes
(VCMs) were selected by dual zeocin-GFP expression under the transcriptional control of the MLC2v promoter
and confirmed electrophysiologically by its signature action potential phenotype. High levels of H3K4me3 are
present on pluripotency genes in hESCs with an absence of H3K27me3. Human ESC-VCMS, relative to hESCs,
were characterized by a profound loss of H3K27me3 and an enrichment of H3K4me3 marks on cardiac-specific
genes, including MYH6, MYH7, MYL2, cTNT, and ANF. Gene transcripts encoding key voltage-gated ion
channels and Ca2 + -handling proteins in hESC-VCMs were significantly increased, which could be attributed to a
distinct pattern of differential H3K4me3 and H3K27me3 profiles. Treatment of hESC-VCMs with the histone
deacetylase inhibitor valproic acid increased H3K4me3 on gene promoters, induced hypertrophic growth (as
gauged by cell volume and capacitance), and augmented cardiac gene expression, but it did not affect elec-
trophysiological properties of these cells. Hence, cardiac differentiation of hESCs involves a dynamic shift in
histone methylation, which differentially affects VCM gene expression and function. We conclude that the
epigenetic state of hESC-VCMs is dynamic and primed to promote growth and developmental maturation, but
that proper environmental stimuli with chromatin remodeling will be required to synergistically trigger global
CM maturation to a more adult-like phenotype.
Introduction
Human embryonic stem cells (hESCs) are pluripotentcells that can indefinitely propagate in culture and
differentiate into virtually any cell type [1]. Since adult car-
diomyocytes (CMs) are terminally differentiated and non-
regenerative, significant loss of functional CMs due to aging
or myocardial infarction can lead to lethal consequences.
Using in vitro differentiation methods, ventricular (V) CMs
derived from hESCs are considered as a valuable source for
potential cell-based heart therapies and as experimental
models for human heart diseases [2–6]. Previous studies have
examined various biological properties of hESC-derived
ventricular cardiomyocytes (VCMs), including ion channel
development, action potential (AP), Ca2 + transients, and
propagation of electrical signals [7–10]. Despite the expression
of cardiac-specific transcription factors and structural pro-
teins in the hESC-VCMs, it is now widely accepted that both
the Ca2 + handling and electrophysiological properties of
hESC-VCMs are immature (reviewed in [11]) with an un-
derlying basis that is very poorly understood. Furthermore,
hESC-VCMs are typically 5 to 10 times physically smaller
than adult VCMs, and can generate contractile forces that are
only a fraction of the adult level.
Chromatin modifications and epigenetic changes are cen-
tral to the regulation of gene expression [12,13]. In particular,
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histone modifications, including acetylation, methylation,
phosphorylation, and ubiquitination, have received consid-
erable attention in recent years [14–18]. Different histone
modification patterns form histone codes, providing spe-
cialized binding surfaces that recruit protein complexes
containing chromatin remodeling and transcriptional acti-
vation or repression activities [19,20]. Recent studies at the
genome-wide level have identified important chromatin
patterns of the embryonic epigenetic landscape. During the
course of development, a balance between active (H3K4me3-
enriched) and silent (H3K27me3-enriched) transcription is
maintained by specific histone methyltransferases [21]. The
repression of tissue-specific and developmental genes in
pluripotent ESC is temporary and dynamic, and is based on
the presence of bivalent chromatin domains, which are
composed of active (H3K4me3) and repressive marks
(H3K27me3), allowing them to become rapidly activated
when required at a later stage of development [22–25].
With the key objective of understanding the epigenetic
regulation in hESC-VCMs, in this report, using chromatin
immunoprecipitation (ChIP) assays, patch-clamp and Ca2 + -
imaging techniques, we examined the histone methylation
status of hESC-VCMs on genes that are known to associate
with pluripotency, cardiac functions, Ca2 + handling, and
crucial ion channels. Collectively, our findings present that
dynamic changes in epigenetic landscape in the context of
histone methylation-mediated transcriptional regulation un-
derlie human CM development and function.
Materials and Methods
Maintenance and cardiac differentiation of HES2
The hESC line, HES2, was maintained in 37C with a 5%
CO2 incubator in an mTeSR
1 culture medium (Stem Cell
Technologies). A directed differentiation protocol was used
to differentiate HES2 into cardiac lineage using the activin
A, bone morphogenetic protein-4 (BMP-4), and vascular
endothelial growth factor (VEGF) induction, as reported
[26]. In brief, on Day 0, HES2 were cultured in suspension to
form cardiosphere aggregates using BMP4 (0.5 ng/mL). Day
1–4, the aggregates were incubated in media containing
BMP4 (5 ng/mL), basic fibroblast growth factor (bFGF)
(5 ng/mL), and activin A (3ng/mL). Day 4–8, activin A and
BMP4 were removed, and replenished with VEGF (10 ng/
mL) and human Dickkopf homolog 1 (150ng/mL). After
Day 8, the cardiospheres were maintained in VEGF (10 ng/
mL) and bFGF (5 ng/mL). The differentiation cultures were
maintained in 5% CO2/5% O2/90% N2 environment for the
first 12 days, and then transferred into a normal 5% CO2
incubator. Fresh media is supplied every 3 to 4 days.
Isolation and selection of hESC-VCMs
HESC-derived CMs are heterogeneous, containing a mix-
ture of ventricular, atrial, and pacemaker derivatives [7,8]. To
eliminate noncardiac cells and purify hESC-VCMs, cardio-
spheres were dissociated and replated as single cells on Day
17, and transduced with recombinant lentivirus particle, LV-
MLC2v-GFP-t2A-zeo at MOI of 5 on Day 18. Zeocin
(300 mg/mL) (Life Technologies) was added to the trans-
duced cells from Day 22 to Day 27 to eliminate non-
ventricular CMs. The effectiveness using MLC2v-promoter
lentivirus for ventricular CM selection has been reported
previously [27,28].
Histone deacetylase complex inhibition
Zeocin selected hESC-VCMs were exposed to valproic
acid (VPA) (Sigma Chemical Co., Ltd.) at 2mM for 48 h. VPA
was prepared in the Dulbecco’s modified Eagle medium
culture medium containing 5% fetal bovine serum.
cDNA synthesis and gene expression analysis
by real-time PCR
cDNA were prepared using the SuperScript CellsDirect
cDNA Synthesis Kit (Life Technologies) following the pro-
tocol recommended by the manufacturer. Gene expressions
were quantified using StepOnePlus Real-Time PCR system
(Applied Biosystems). PCR amplifications were carried out
in 96-well optical plates with 20 mL reaction volume, con-
sisting of 100 ng of cDNA template, 5 pmol of forward and
reverse primers, and 1 ·Power SYBR Green PCR Master
Mix (Applied Biosystems). The reactions were incubated at
95C for 10min, and followed by 40 to 50 cycles of 95C for
15 s and 60C for 60 s. Primer sequences are available upon
request.
ChIP assay
The ChIP assay was carried out using the EZ Magna
ChIP A/G Kit (Millipore) following the protocol re-
commended by the manufacturer. In brief, isolated cells
(5· 106 cells) were crosslinked in a 1% formaldehyde solu-
tion, and then quenched by the addition of 0.125M glycine.
The crosslinked cells were then resuspended in a sodium
dodecyl sulfate (SDS) lysis buffer, and the soluble chromatin
was sheared to 200–500 bp in length by sonication. Protein
A/G magnetic beads and 5mg of antibodies (H3K4me3–
Millipore 07-473 or H3K27me3–Millipore 07-449) were ad-
ded to the fragmented chromatin and incubated for 2 h at
4C with rotation. The immunocomplexes were collected by
a magnetic separator, washed, and DNA was eluted with 1%
SDS and 0.1M NaHCO3. DNA was purified using spin
columns, and enrichment of specific histone modifications on
gene promoters were quantified by real-time PCR as de-
scribed above. Control ChIPs were also carried out to test
antibody specificity using either no antibody or normal IgG.
Primer sequences are available upon request.
Electrophysiology
For electrical recording, the whole-cell configuration of the
patch-clamp technique was used with an EPC-10 amplifier
and Pulse software (Heka Elektronik). Patch pipettes were
prepared from 1.5-mm thin-walled borosilicate glass tubes
using a Sutter micropipette puller P-97 and had typical re-
sistances of 3-5MO when filled with an internal solution
containing 110mM K+ aspartate, 20mM KCl, 1mM MgCl2,
0.1mM Na-GTP, 5mM Mg-ATP, 5mM Na2-phospocreatine,
1mM EGTA, 10mM HEPES, pH adjusted to 7.3 with KOH.
The external Tyrode’s bath solution consisted of 140mM
NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2, 10mM glucose,
10mM HEPES, pH adjusted to 7.4 with NaOH. The tip po-
tential was zeroed before the patch pipette contacted the cell.
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Upon seal formation and followed by patch break, the ca-
pacitance compensation was applied. Series resistance com-
pensation was used up to 80%. APs were recorded with the
current-clamp mode. Experiments were performed at 37C.
Calcium imaging
The intracellular Ca2 + ([Ca2 + ]i) transients were analyzed
by loading the cells with 1.5 mM X-Rhod-1 (Invitrogen) for
10min at 37C in the Tyrode’s solution containing 140mM
NaCl, 5mM KCl, 1mM MgCl2, 1.25mM CaCl2, 10mM
HEPES and 10 D-glucose at pH 7.4), followed by imaging
with a spinning disc laser confocal microscope (Perki-
nElmer). The electrically induced Ca2 + transients (E[Ca2 + ]i)
were triggered by pulses (40ms pulse duration; 40V/cm;
1Hz) generated from a field generator. The amplitudes of
Ca2 + transients are presented as the background corrected
pseudoratio (DF/F)1,2 = (F-Fbase)/(Fbase-B), where Fbase and F
is the measured fluorescence intensity before and after
stimulation, respectively, and B is the average background
signal from areas adjacent to the targeted cell. The transients
rise (Vupstroke) and the transients decay (Vdecay) were subse-
quently calculated and analyzed.
Cell volume
The cell volume of hESC-VCMs was determined by im-
munostaining the fluorescent dye CellTracker Green (In-
vitrogen). A z-stack image was then obtained with a confocal
microscope (Carl Zeiss LSM 510 meta). The 3D image was
constructed and cell volume was estimated with the image
analysis software Imaris.
Immunofluorescence imaging
hESC-VCMs were fixed with 4% paraformaldehyde and
permeabilized with 0.05% Triton X-100. After blocking with
3% bovine serum albumin overnight, cells were incubated
with the primary antibody for 2 h (Sarcomeric alpha actinin
[EA-53]–Abcam ab9465; Cardiac troponin T [1F11]–Abcam
ab10214; Myosin light chain 2–Abcam ab79935; SERCA2
ATPase [2A7-A1]–Abcam ab2861, atrial natriuretic peptide
(ANP)–Abcam ab76743) followed by incubation with fluo-
rescent-conjugated secondary antibodies (Alexa Fluor 488 or
555–Life Technologies). Fluorescence images were captured
and analyzed using Spot Advance software (Spot Imaging
Solutions). The percentage of ANP natriuretic peptide type A
(NPPA)-positive cells was calculated by counting the number
of cells with a strong perinuclear fluorescence signal around
the nucleus stained by DAPI (ProLong Gold Antiface Re-





As reported previously, the expression of a reporter protein
driven by the ventricular myosin light chain (MLC2v) pro-
moter enables the identification and isolation of hESC-VCMs
[27,28]. In these experiments, LV-MLC2v-GFP-t2A-zeo trans-
duction was performed, followed by zeocin selection. Figure
1A, B shows a typical pure population of zeocin-selectedGFP+
cells thatwere positively immunostained for cTNT,MLC2v, a-
sacromeric actinin, and SERCA2a. Electrophysiologically, all
of the GFP+ cells (n= 30) displayed an AP waveform (Fig. 1C)
as well as electrically elicited Ca2 + transients (Fig. 1D) that
were typical of hESC-VCMs. Throughout this study, only se-
lected hESC-VCMs were examined to avoid ambiguities due
to the presence of other chamber-specific types.
Distinct gene expression profiles of hESCs
and hESC-VCMs
As a first step, we compared the differential intensity ob-
tained from microarray profiling [28] of undifferentiated
hESCs and hESC-VCMs. Supplementary Figure S1(Supple-
mentary Data are available online at www.liebertpub.com/
scd) shows a unique pattern of increased abundances for
cardiac-specific genes, Ca2 + -handling proteins, and various
cardiac ion channels in hESC-VCMs compared to hESCs;
conversely, signal intensities of pluripotency markers,
including OCT4, SOX2, and NANOG, were significantly re-
duced in hESC-VCMs. To validate this trend, the expression
levels of several representative pluripotency and cardiac
genes in hESCs and hESC-VCMs were further assessed using
quantitative real-time PCR. As shown in Fig. 2A, hESC-
VCMs expressed markers of mesodermal lineage commit-
ment, MESP1, and cardiac progenitor, ISL1. There was also a
significant increase in the expression of the cardiac tran-
scription factor Nkx2.5 as well as the cardiac-specific genes
cTNT and MLC2v. By contrast, transcripts of pluripotency,
including OCT4 and NANOG, were significantly expressed in
hESCs, but not hESC-VCMs (Fig. 2B). As for Ca2+ -handling
proteins (Fig. 2C), phospholamban (PLN), dihydropyridine
receptor (DHPR), ryanodine receptor 2 (RYR2), junction
(ASPH/JCTN), ATPase calcium transporting cardiac muscle
slow twitch 2 (ATP2A2/SERCA2), calreticulin (CALR), calse-
questrin2 (CASQ2), and triadin (TRDN) all showed a significant
increase in their expression levels in hESC-VCMs compared
to hESCs. Of note, mRNA transcripts of PLN and CASQ2
were below detectable levels in undifferentiated hESCs. Simi-
larly, examination of voltage-gated sodium channel—SCN5A
(Nav1.5)—hyperpolarization-activated cyclic nucleotide-gated
potassium channel—HCN1, HCN2, and HCN4—and voltage-
gated potassium channels—KCNA4 (Kv1.4), KCND3 (Kv4.3),
KCNH2 (ERG1), and KCNJ2 (Kir2.1)—were all upregulated in
the hESC-VCMs. No significant difference was detected for
HCN3, as the levels of mRNA transcripts were low in both
hESCs and hESC-VCMs. Summary of the gene expression an-
alyses is shown in Supplementary Table S1.
Differential enrichment of H3K4tri-methylation
and H3K27tri-methylation on gene promoters
The presence of specific methylation marks on gene pro-
moters has been associated with transcriptional regulation.
Using ChIP, the levels of H3K4 tri-methylation (H3K4me3—
associated with active transcription) and H3K27 tri-methyl-
ation (H3K27me3—associated with repressed transcription)
on gene promoters (< 1000 bp from transcriptional initiation
site) were compared between hESCs and hESC-VCMs. On
promoters of pluripotency genes, OCT4, SOX2, and NANOG,
there was an accumulation of H3K4me3 in hESCs (Fig. 3A),
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whereas H3K27me3 was enriched on these regions in hESC-
VCMs (Fig. 4A). Conversely, H3K27me3 was significantly
higher on cardiac genes in hESCs (Fig. 4B), but H3K4me3
was enriched on the MLC2v, MLC2a, cTNT, and NPPA pro-
moters in hESC-VCMs (Fig. 3B). These results correlated
with the gene expression data. The interplay between
H3K4me3 and H3K27me3 were similarly studied on the
cardiac ion channel and Ca2 + -handling genes. While there
was a significant increase in H3K4me3 on the PLN, DHPR,
ASPH, TRDN, SCN5A, and KCNA4 promoters in hESC-
VCMs when compared to hESCs (Fig. 3C, D), reduction in
H3K27me3 is observed on PLN, CALR, CASQ2, and TRDN
promoters (Fig. 4C). No statistical differences were detected
for H3K27me3 and H3K4me3 on the promoters of other
cardiac ion channels and proteins examined (e.g., RYR2,
SERCA2, HCN1-4, KCND3, KCNH2, and KCNJ2; Figs. 3 & 4).
FIG. 1. Characterization of zeocin selected MLC2v-GFP-positive human embryonic stem cell-derived ventricular cardio-
myocytes (hESC-VCMs). (A) Brightfield (left panel) and fluorescence (right panel) imaging of LV-MLC2v-GFP-t2A-zeo-
transduced hESC-CMs after 7 days of zeocin selection. Images were captured at 10·magnification. (B) Immunofluorescence
staining of cTnT, MLC2v, a-sacromeric actinin, and SERCA2a of hESC-VCMs. Images were captured at 40 ·magnification.
(C) Representative tracing of action potential (AP) and (D) electrically induced Ca2 + transient in hESC-VCMs at 1Hz. Color
images available online at www.liebertpub.com/scd
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Histone deacetylase complex inhibition induced
physical maturation in hESC-VCMs without
altering their electrophysiological
and Ca2 + -handling properties
Histone deacetylase (HDAC) inhibitors have often been
used to hyperacetylate histone tails to increase the accessi-
bility for the binding of transcription factors to promoters for
gene activation. VPA (2-propylpentanoic acid) is structurally
similar to the well-known HDAC inhibitors, such as sodium
butyrate and phenylbutyrate, but it is less potent in terms of
inhibition of HDAC than the hydroxymate class, which in-
cludes Trichostatin A (TSA) and suberoylanilide hydroxamic
acid [29]. Western blotting analysis indicated that 72-h
incubation of hESC with 2mM VPA resulted in the accu-
mulation of hyperacetylated histone H3 and H4 (Fig. 5A).
Furthermore, the active transcription mark, H3K4me3, was
enhanced upon VPA treatment. To examine the effect of
HDAC inhibition on hESC-VCMs, cells were likewise exposed
to 2mM VPA for 72h, followed by examining any transcrip-
tion changes by quantitative real-time PCR. There was 1.5- to
3.5-fold increase in the expression of genes associated with
Ca2+ pump and K+ ion channels (Fig. 5B, C) in the VPA-
treated hESC-VCMs. The expression of cardiac markers,
MYH6 (a-MHC), and hypertrophy markers, NPPA (ANF), also
increased by 1.9- and 1.6-fold, respectively (Fig. 5D). Im-
munofluorescence imaging showed the accumulation of NPPA
in the hESC-VCMs at 72h following VPA treatment (Fig. 5E).
By counting and measuring the percentage of cell with the
perinuclear atrial natriuretic factor (ANF), it is found that 31%
of the control hESC-VCMs and 51% of the VPA-treated hESC-
VCMs were ANF-positive (Fig. 5F). In addition to the global
increase of H3K4me3 upon VPA treatment, immunoprecipi-
tation of H3K4me3-bounded DNA indicated that there was an
FIG. 2. Quantitative real-time PCR analysis of gene expression in hESCs and hESC-VCMs. The levels of mRNA transcripts
of (A) cardiac-related genes [MESP1, ISL1, NKX2.5, (TNNT) cTNT, andMYL2 (MLC2v)], (B) pluripotency markers (OCT4 and
NANOG), (C) Ca2 + -handling proteins (PLN, DHPR, RYR2, ASPH, ATP2A2, CALR, CASQ2, and TRDN), and (D) sodium and
potassium ion channels [SCN5A (Nav1.5), HCN1-4, KCNA4 (Kv1.4), KCND3 (Kv4.3), KCNH2 (ERG1), and KCNJ2 (Kir2.1)] in
hESCs and hESC-VCMs were compared using quantitative real-time PCR. Fold change of mRNA expression shown are
relative to hESCs, and mean– standard deviations of three independent experiments are indicated. *P< 0.05, **P < 0.01,
***P < 0.001 and n.s., not statistically significant (Student’s t-test).
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enrichment of this active transcription mark at the chromatin
level, by 3- to 10-fold, on the gene promoters of Ca2+ -pump
functions and ion channels (Fig. 5G). Of interest, the level of
H3K4me3 on the NPPA promoter was 91-fold higher in the
hESC-VCMs after VPA treatment.
Despite increased gene expression of Ca2 + -handling pro-
teins and ion channels, hyperacetylation of histone tails by
VPA did not lead to significant electrophysiological changes
of hESC-VCMs. The percentages of hESC-VCMs that could
be captured by electrical stimulations were similar between
hESC-VCMs with or without exposure to VPA (P > 0.05).
There were also no significant differences in the baseline
Ca2 + -transient amplitude, upstroke velocity, and decay ve-
locity between the untreated controls (noncaptured n = 43;
captured n = 12) and the hESC-VCMs incubated with 2mM
of VPA for 72 h (noncaptured n = 25; captured n = 20)
(Table 1). Representative Ca2 + -transient traces are shown in
Fig. 6A. HESC-VCMs were also examined for their respon-
siveness to b-adrenergic stimulation. Among the hESC-
VCMs that captured electrical stimulation, b-agonist
isoproterenol (ISO) led to a positive chronotropic response,
but failed to elicit any inotrophic effects on cells as no sig-
nificant difference in Ca2 + -transient parameters was detected
(untreated n = 7; VPA-treated n = 12) (Table 1), consistent
with untreated control. In the AP analysis by patch clamp,
the electrical properties of the control (n = 25) and VPA-
treated (n= 23) hESC-VCMs were similar with no statistical
significance (Fig. 6B), but VPA treatment promoted cell en-
largement as indicated by the significant increase in mem-
brane capacitance (Fig. 6C, Table 2). In complete accordance
with these observations, hESC-VCMs immunostained by
CellTracker Green for cell volume measurement were
FIG. 3. The levels of H3K4tri-methylation on gene promoters in hESCs and hESC-VCMs. Soluble chromatin of hESCs and
hESC-VCMs were immunopurified using the H3K4me3 antibody and quantitative real-time PCR was used to measure the
level of enrichment on gene promoters associated with (A) pluripotency, (B) cardiac-related genes, (C) Ca2 + -handling
proteins, and (D) sodium and potassium ion channels. Data were normalized to input chromatin and relative to the level of
enrichment on the GAPDH promoter (transcriptionally active). Mean – standard deviations of three independent experiments
are presented. *P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t-test).
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almost three times larger in VPA-treated hESC-VCMs
(n = 18) than untreated controls (n = 18) (Fig. 6D).
Discussion
Characterization of the histone methylation profile and
transcriptional regulation of genes encoding for Ca2 + -han-
dling proteins and cardiac ion channels in this study provide
molecular insights of the epigenetic mechanism associated
with the electrophysiology functions of hESC-VCMs. In
particular, we showed that upon cardiac differentiation, the
upregulation of cardiac-specific genes and downregulation
of pluripotency maintenance genes are tightly correlated
with H3K4me3 (active transcription mark) and H3K27me3
(silent transcription mark). Epigenetic manipulation with a
HDAC inhibitor, VPA, increased the expression of genes
associated with Ca2 + -handling proteins and cardiac ion
channels, with the enrichment of active H3K4me3 marks on
their corresponding gene promoters. Finally, we extended
our study to investigate the effect of VPA treatment on the
electrophysiology functional properties of CMs. In the pro-
cess, we discovered that VPA treatment appears to induce
developmental hypertrophic growth, as gauged by cell vol-
ume and membrane capacitance. These results are further
discussed below in the context of driven maturation and
mechanistic insights.
Distinct modes of histone modification regulations:
hESC-VCMs are epigenetically primed
for maturation, but need triggering
environmental stimuli
Gene transcription is tightly regulated by three important
epigenetic mechanisms, DNA methylation, post-translational
FIG. 4. The levels of H3K27tri-methylation on gene promoters in hESCs and hESC-VCMs. Soluble chromatin of hESCs and
hESC-VCMs were immunopurified using the H3K27me3 antibody and quantitative real-time PCR was used to measure the
level of enrichment on genes associated with (A) pluripotency, (B) cardiac-related genes, (C) Ca2 + -handling proteins, and (D)
sodium and potassium ion channels. Data were normalized to input chromatin and relative to the level of enrichment on the
Satelite1 region (transcriptionally silenced). Mean – standard deviations of three independent experiments are presented.
*P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t-test).
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modifications of histones, and ATPase-dependent chromatin
remodeling [30]. Chromatin determinants and transcription
factors function together for genes to be selectively activated
or silenced in response to chemical and environmental
stimuli [31]. Previous studies have demonstrated that the
H3K4-methylation complex is essential for stabilizing gene
expression and physiological functions of CMs [32]. Also, the
upregulation of Nkx2.5 is accompanied by the increase of
histone H3 and H4 acetylation and the reduction of HDAC1
expression [33]. The histone tails ofMYH6 is also targeted by
histone acetyltransferases in CMs [34]. Using the hESC-
VCMs generated by directed differentiation, we not only
observed the fundamental changes in gene regulation, in-
cluding the loss of pluripotency-related genes expression,
accompanied by the high expression of mesodermal and
cardiac-related genes, we also demonstrated the activation of
important genes encoding for proteins that are responsible
for the control of Ca2 + pumping and ion transports between
the cytoplasm and sarcoplasmic reticulum lumen. In undif-
ferentiated hESCs, the active OCT4, SOX2, and NANOG
promoters are enriched by the active transcription mark—
H3K4me3. Upon CM differentiation, H3K4me3 is lost on
these pluripotency gene promoters and the enrichment of
H3K27me3 is observed. Furthermore, for the establishment
of CM development, dynamic changes of the persisting
epigenetic marks occur to create a chromosomal environ-
ment that favors the upregulation of genes responsible for
CM contraction, Ca2 + handling, and cardiac ion channels.
Our results are consistent with recent next generation se-
quencing (ChIP-sequencing (SEQ) and RNA-SEQ) analyses,
which provide insights for the underlying regulatory mech-
anism that controls developmental transition in the cardiac
lineage [35,36]; specific chromatin regulatory patterns are
shared among functionally related and coexpressed genes for
precise coordination of CM differentiation and development
in mouse and human ESC cardiac differentiation models
[35,36]. Interesting findings from genome-wide ChIP-SEQ
reveal that unlike early lineage-specific genes that possess
bivalent domain on the promoters in undifferentiated state,
different subsets of cardiac-related genes have distinct his-
tone methylation landscapes and are not entirely regulated
by bivalent methylation. While a complete reversal of active
and silent histone marks is found on pluripotency-associated
gene promoters, upon CM differentiation, genes involved in
mesoderm formation are highly expressed despite being
heavily marked by H3K27me3 [36]. Developmental regula-
tors such as cardiac-specific transcription factors are highly
enriched for H3K27me3 in the undifferentiated state, which
gradually decrease as H3K4me3, H3K36me3, and mRNA ex-
pression appear. In contrast, genes encoding for CM contractile
and structural proteins, do not have high levels of H3K27me3
deposition at any time [36]. These distinct modes of histone
modification regulations have been suggested to exist to en-
sure that particular gene sets of specific functions can be
switched on simultaneously. This is consistent with our pos-
tulation that the hESC-VCMs are primed to maturation, but
need to be stimulated by the right signals or environmental
stimuli. Indeed, we have reported that by mimicking endog-
enous fetal heart pacing by field stimulation in culture, the
regulated rhythmic electrical conditioning of hESC-CMs pro-
motes in vitro electrophysiological Ca2+ handling, as well as
contractile maturation with more organized myofilaments [37].
Combinatorial approach for driving global
maturation
An epigenetic drug that possesses a known inhibitory
effect on HDACs was used in this study to modify the
transcriptional regulation in hESC-VCMs. Use of HDAC in-
hibitors in ESC differentiation has been previously reported.
For instance, TSA facilitates myocardial differentiation of the
murine induced pluripotent stem cell [38] and increases
acetylation of GATA-binding protein-4 to promote differen-
tiation of murine ESCs into CMs [39]. VPA is a Food and
Drug Administration approved drug that is clinically used
as an anticonvulsant, and a mood stabilizing drug for the
treatment of epilepsy and bipolar disorder [40]. Recently,
VPA has been shown to increase histone acetylation of
histone H3 and H4, as well as enhance mono-, di-, and tri-
methylation at H3K4 [41,42]. The addition of VPA in hESC-
VCM culture augmented the expression of genes important
for electrophysiological functions. While no significant dif-
ference in AP and Ca2 + -transient properties was observed,
VPA application induces developmental hypertrophic
growth, as gauged by cell volume and capacitance, of hESC-
VCMs that are typically physically 5 to 10 times smaller than
the adult. It is possible that in addition to building an
epigenetic state that is appropriate for improving electro-
physiological functions, a combinatorial approach of simul-
taneously introducing proper environmental stimuli can
couple with chromatin remodeling to synergistically trigger
global CM maturation.
To improve the immature electrophysiology, inefficient
excitation–contraction coupling and weak contractile force in
FIG. 5. Valproic acid (VPA) increased mRNA expression of Ca2 + -handling proteins and ion channel genes, and induced
hypertrophy of hESC-VCMs. (A) hESCs were treated with 2mM of VPA or 50 ng/mL of Trichostatin A (TSA) for 72 h and
protein extracts were resolved on sodium dodecyl sulfate–polyacrylamide gel electrophoresis and analyzed by western
blotting with either acetyl-H3, acetyl-H4, or H3K4me3 antibodies. Total histone H4 and GAPDH were used to demonstrate
equivalent protein loading. hESC-VCMs were treated with 2mM of VPA for 72 h and mRNA expression of genes related to
(B) Ca2 + -handling proteins, (C) ion channels, and (D) cardiac hypertrophy were measured by quantitative real-time PCR.
Mean – standard deviations of three independent experiments are presented. *P < 0.05, **P < 0.01 and, ***P < 0.001 (Student’s t-
test). (E) Immunofluorescence staining of a-sacromeric actinin (green) and NPPA (ANF) (red) in control and VPA-treated
hESC-VCMs. The images were captured at 40 ·magnification. (F) Percentage of NPPA (ANF)-positive immunostained cell in
control untreated and VPA-treated hESC-VCMs (results from three independent experiments). (G) Representative data of
H3K4me3 chromatin immunoprecipitation. Soluble chromatin of control and VPA-treated hESC-VCMs were im-
munopurified using the H3K4me3 antibody and quantitative real-time PCR was used to measure the level of enrichment on
gene promoters. Data were normalized to input chromatin and relative to the level of enrichment in control untreated hESC-
VCMs. Color images available online at www.liebertpub.com/scd
‰
EPIGENETIC AND ELECTROPHYSIOLOGICAL FUNCTION OF HESC-VCMs 2685
2686 CHOW ET AL.
hESC-VCMs, re-expression of the proteins important for
these functions are essential. Indeed, microarray data sug-
gest that the gene expression levels of PLN, RYR2, ASPH,
CASQ2, KCND3, KCNH2, and KCNJ2 in the hESC-VCMs are
still lower than the mature CMs [28], and previous studies
that examined the expression of key Ca2 + -handling proteins
and ion channels at the protein level have reported that PLN,
CASQ2, TRDN, and ASPH proteins are absent in the hESC-
VCMs [32,43]. Our group has previously reported that fa-
cilitated maturation by forced expression of CASQ2 can lead
to functional improvements in Ca2 + -handling properties of
hESC-VCMs [44], and overexpression of Kir2.1 alone can
even induce an electrical phenotype indistinguishable from
that of primary adult ventricular cells [37,45,46]. Further in-
vestigation into manipulation of epigenetics, proteins, and
physiological determinants, in combination, can potentially
provide novel means to increase contractility and generate
hESC-VCMs of a more mature state.
HDAC inhibition induces hypertrophic growth
of hESC-VCMs, but their biological actions
are context dependent
HDACs are grouped into four classes (I–IV). Class IIa
HDACs interact with the transcription factor MEF2 to reg-
ulate cardiac hypertrophy. Overexpression of Class IIa
HDACs 4, 5, and 9 suppresses MEF2-dependent transcrip-
tion and agonist-dependent hypertrophy of cultured CMs
[34,47,48]. In contrast, HDAC5 and HDAC9 knockout mice
develop hypertrophy with increased age and show an ex-
aggerated hypertrophic response to pressure overload
[34,49]. On the other hand, Class I HDACs (1 and 2) are
reported to promote hypertrophy. Cardiac-specific over-
expression of HDAC2 in the transgenic mice model develops
cardiac hypertrophy with increased fetal gene expression.
Recent studies have demonstrated that Class IIa HDACs are
actually relatively insensitive to standard HDAC inhibitors
and do not require the catalytic activity to suppress hyper-
trophic signaling in CMs [50]. This is why HDAC inhibitors,
via inactivation of Class I HDACs, generally cause attenua-
tion in hypertrophy [51–54]. However, it should be noted
that the majority of the studies were performed on murine
models and hESC-VCMs used in our study actually repre-
sent an early stage of CM development, resembling imma-
ture fetal-like CMs. While the myosin composition of the
ventricular myocardium of a human has been reported to be
> 95% b-MHC, from examination of myosin gene expression
during CM differentiation, genome-wide microarray, and
proteomics analysis (Supplementary Figs. S1A and S2),
a-MHC seems to be the predominant myosin isoform in
hESC-VCMs. In addition to immature electrophysiology and
contractile properties in the hESC-VCMs, their physical size
is typically 5 to 10 times smaller than adult VCMs. CMs lose
the ability to divide after birth and the adult heart undergoes
cardiac hypertrophy in response to exercise, hormonal
stimuli, and even genetic influences [55]. Although expres-
sion of ANF is a marker of both physiological and patho-
logical hypertrophy in adult ventricular CMs, in the case of
immature fetal ventricular CMs, the expression of ANF is
most consistent with the development of a working myo-
cardium [56].
From whole genome analysis, the expression profiles of
CMs at different developmental stages vary. Our group has
previously demonstrated that miR-1 and - 499 have differ-
ential effects in hESC-VCMs, fetal-VCMs, and adult-VCMs
[10]. Hence, the effect of HDAC inhibition on CMs is also
likely to be context-dependent. Indeed, the amount of NPPA
mRNA transcripts and the percentage of perinuclear ANF in
hESC-VCMs are elevated upon VPA treatment. However, since
the hESC-VCMs are in the early stage of development resem-
bling immature fetal-like heart, where the expression of ANF
generally indicates a functional myocardium that is undergoing
maturation, the upregulation of ANF in VPA-treated hESC-
VCMs suggests that HDAC inhibition induces growth and
physical maturation. In our present study, hypertrophy was
assessed by measurements of capacitance, a physical parameter
that directly reflects the cell size based on the membrane lipid
bilayer; by contrast, a simple increase in the surface area of cells
conventionally grown two-dimensionally may not be due to
an increase in size, but other changes such as cellular senes-
cence or flattening. Indeed, hESC-VCMs are routinely cul-
tured in monolayer forms, and therefore, it is not possible
to assess tissue architecture or hemodynamic load per se, re-
flecting the urgent need of developing three-dimensional ex-
perimental for studying these critical properties.
The involvement of chromatin remodeling is shown
by immunoprecipitation of H3K4me3, where the level of
H3K4me3 is significantly increased on the ANF promoter
Table 1. Ca2 + -Transient Analysis (Calcium Imaging)
Noncaptured Captured
Control (n = 43) VPA (n = 25) Control (n = 12) VPA (n= 20)
Amplitude 0.29 – 0.03 0.27 – 0.03 0.29 – 0.05 0.24 – 0.35
Upstroke velocity 0.89 – 0.10 0.87 – 0.10 1.27 – 0.26 0.91 – 0.16
Decay velocity - 0.35 – 0.03 - 0.45 – 0.06 - 0.47 – 0.12 - 0.34 – 0.05
Untreated hESC-VCM (n= 7) VPA-treated hESC-VCM (n = 13)
Control Control + ISO VPA VPA + ISO
Amplitude 0.37 – 0.07 0.31 – 0.05 0.23 – 0.05 0.15 – 0.04
Upstroke velocity 1.62 – 0.35 1.39 – 0.27 0.88 – 0.24 0.64 – 0.16
Decay velocity - 0.62 – 0.15 - 0.79 – 0.17 - 0.35 – 0.08 - 0.34 – 0.07
hESC, human embryonic stem cell; VPA, valproic acid; ISO, isoproterenol.
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following exposure to VPA. Furthermore, the VPA treatment
shows increased levels of Ca2 + handling and cardiac ion
channel gene expressions. However, it remains to be deter-
mined if this transient inhibition of HDAC could have
elicited an epigenetic memory in the CMs as with compli-
cations of diabetes, where endothelial cells with prior expo-
sure of hyperglycemia lead to various histone methylation
and demethylation events that impact on the gene activity,
where proinflammatory pathways are permanently activated
[57]. Further understanding of the chromatin remodeling
events and how they are linked to cardiac differentiation and
maturation will lead to better strategies to pluripotent stem
cell-based disease modeling and therapies.
Table 2. Action Potential Analysis (Patch Clamp)
Control (n= 43) VPA (n = 25)
Amplitude (mV) 84.16 – 2.97 81.23– 2.17
Upstroke velocity (mV/ms) 19.15 – 2.19 22.88– 2.53
Decay velocity (mV/ms) - 0.42 – 0.05 - 0.52 – 0.24
APD50 (ms) 268.85 – 46.86 233.28– 26.13
ADP90 (ms) 351.14 – 54.05 291.66– 27.33
MDP (mV) - 62.61 – 1.73 66.04– 1.78
Membrane capacitance (pF) 59.77 – 4.69 100.17– 9.24*
*P< 0.05.
FIG. 6. VPA has no signifi-
cant effects on the electro-
physiological properties of
hESC-VCMs. HESC-VCMs
were treated with 2mM of
VPA for 72 h and the electro-
physiology parameters were
measured by calcium imag-
ing and patch clamp. Re-
presentative (A) Ca2 + -
transient and (B) AP tracings
of control and VPA-treated
hESC-VCMs. (C) Membrane
capacitance of control and
VPA-treated hESC-VCMs
(results from three indepen-
dent experiments). *P < 0.05
(Student’s t-test). (D) The cell
volume measured by z-stack
image obtained from immu-
nofluorescence imaging. Data
shown as mean – standard
deviations. ***P < 0.001 (Stu-
dent’s t-test).
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Conclusion
In conclusion, this study describes a dynamic shift of
transcription determining histone methylation marks on the
promoters of genes associated with pluripotency mainte-
nance, mesodermal and cardiac lineage, Ca2 + -handling
proteins, and cardiac ion channels in hESCs upon directed
CM differentiation. The introduction of transient HDAC in-
hibition in hESC-VCMs amplifies the expression level of
specific genes important for CM functions. The fact that
discrete histone modifications have been uncovered on both
active and silent promoters highlights the importance of the
orchestration of epigenetic mechanisms in transcriptional
regulation, and therefore, the phenotype of hESC-VCMs. We
conclude that although hESC-VCMs display immature
structural and functional properties, their epigenetic state is
dynamic and when appropriately activated, display traits
consistent with maturation. These findings raise the intrigu-
ing possibility of using epigenetic modifiers in combination
with other promaturation stimuli such as environmental cues
to drive in vitro global maturation of hESC-VCMs toward an
adult-like phenotype.
Acknowledgment
This work was supported by grants from the Research
Grant Council (TBRS T13-706/11 and GRF 103544).
Author Disclosure Statement
No competing financial interests exist.
References
1. Thomson JA, J Itskovitz-Eldor, SS Shapiro, MA Waknitz, JJ
Swiergiel, et al. (1998). Embryonic stem cell lines derived
from human blastocysts. Science 282:1145–1147.
2. Blin G, D Nury, S Stefanovic, T Neri, O Guillevic, et al.
(2010). A purified population of multipotent cardiovascular
progenitors derived from primate pluripotent stem cells
engrafts in postmyocardial infarcted nonhuman primates.
J Clin Invest 120:1125–1139.
3. Blin G, T Neri, S Stefanovic and M Puceat. (2010). Human
embryonic and induced pluripotent stem cells in basic and
clinical research in cardiology. Curr Stem Cell Res Ther
5:215–226.
4. Yi BA, O Wernet and KR Chien. (2010). Pregenerative
medicine: developmental paradigms in the biology of car-
diovascular regeneration. J Clin Invest 120:20–28.
5. Laflamme MA, KY Chen, AV Naumova, V Muskheli, JA
Fugate, et al. (2007). Cardiomyocytes derived from human
embryonic stem cells in pro-survival factors enhance func-
tion of infarcted rat hearts. Nat Biotechnol 25:1015–1024.
6. Irion S, MC Nostro, SJ Kattman and GM Keller. (2008). Di-
rected differentiation of pluripotent stem cells: from devel-
opmental biology to therapeutic applications. Cold Spring
Harb Symp Quant Biol 73:101–110.
7. He JQ, Y Ma, Y Lee, JA Thomson and TJ Kamp. (2003).
Human embryonic stem cells develop into multiple types of
cardiac myocytes: action potential characterization. Circ Res
93:32–39.
8. Moore JC, J Fu, YC Chan, D Lin, H Tran, et al. (2008). Dis-
tinct cardiogenic preferences of two human embryonic stem
cell (hESC) lines are imprinted in their proteomes in the
pluripotent state. Biochem Biophys Res Commun 372:553–
558.
9. Liu J, JD Fu, CW Siu and RA Li. (2007). Functional sarco-
plasmic reticulum for calcium handling of human embry-
onic stem cell-derived cardiomyocytes: insights for driven
maturation. Stem Cells 25:3038–3044.
10. Lieu DK, J Liu, CW Siu, GP McNerney, HF Tse, et al. (2009).
Absence of transverse tubules contributes to non-uniform
Ca(2 + ) wavefronts in mouse and human embryonic stem
cell-derived cardiomyocytes. Stem Cells Dev 18:1493–1500.
11. Poon E, CW Kong and RA Li. (2011). Human pluripotent
stem cell-based approaches for myocardial repair: from the
electrophysiological perspective. Mol Pharm 8:1495–1504.
12. Klose RJ and Y Zhang. (2007). Regulation of histone meth-
ylation by demethylimination and demethylation. Nat Rev
Mol Cell Biol 8:307–318.
13. Ruthenburg AJ, H Li, DJ Patel and CD Allis. (2007). Multi-
valent engagement of chromatin modifications by linked
binding modules. Nat Rev Mol Cell Biol 8:983–994.
14. Bannister AJ and T Kouzarides. (2011). Regulation of chro-
matin by histone modifications. Cell Res 21:381–395.
15. Schneider R, AJ Bannister, FA Myers, AW Thorne, C Crane-
Robinson, et al. (2004). Histone H3 lysine 4 methylation
patterns in higher eukaryotic genes. Nat Cell Biol 6:73–77.
16. Goldberg AD, CD Allis and E Bernstein. (2007). Epigenetics:
a landscape takes shape. Cell 128:635–638.
17. Jenuwein T and CD Allis. (2001). Translating the histone
code. Science 293:1074–1080.
18. Rada-Iglesias A and J Wysocka. (2011). Epigenomics of hu-
man embryonic stem cells and induced pluripotent stem
cells: insights into pluripotency and implications for disease.
Genome Med 3:36.
19. Couture JF and RC Trievel. (2006). Histone-modifying en-
zymes: encrypting an enigmatic epigenetic code. Curr Opin
Struct Biol 16:753–760.
20. Campos EI and D Reinberg. (2009). Histones: annotating
chromatin. Annu Rev Genet 43:559–599.
21. Schwartz YB and V Pirrotta. (2007). Polycomb silencing
mechanisms and the management of genomic programmes.
Nat Rev Genet 8:9–22.
22. Barski A, S Cuddapah, K Cui, TY Roh, DE Schones, et al.
(2007). High-resolution profiling of histone methylations in
the human genome. Cell 129:823–837.
23. Bernstein BE, TS Mikkelsen, X Xie, M Kamal, DJ Huebert, et
al. (2006). A bivalent chromatin structure marks key devel-
opmental genes in embryonic stem cells. Cell 125:315–326.
24. Mikkelsen TS, M Ku, DB Jaffe, B Issac, E Lieberman, et al.
(2007). Genome-wide maps of chromatin state in pluripotent
and lineage-committed cells. Nature 448:553–560.
25. Guenther MG, SS Levine, LA Boyer, R Jaenisch and RA
Young. (2007). A chromatin landmark and transcription
initiation at most promoters in human cells. Cell 130:77–88.
26. Yang L, MH Soonpaa, ED Adler, TK Roepke, SJ Kattman, et
al. (2008). Human cardiovascular progenitor cells develop
from a KDR + embryonic-stem-cell-derived population.
Nature 453:524–528.
27. Fu JD, P Jiang, S Rushing, J Liu, N Chiamvimonvat, et al.
(2010). Na +/Ca2 + exchanger is a determinant of excitation-
contraction coupling in human embryonic stem cell-derived
ventricular cardiomyocytes. Stem Cells Dev 19:773–782.
28. Fu JD, SN Rushing, DK Lieu, CW Chan, CW Kong, et al.
(2011). Distinct roles of microRNA-1 and - 499 in ventricular
specification and functional maturation of human embry-
onic stem cell-derived cardiomyocytes. PLoS One 6:e27417.
EPIGENETIC AND ELECTROPHYSIOLOGICAL FUNCTION OF HESC-VCMs 2689
29. Marks PA, VM Richon, WK Kelly, JH Chiao and T Miller.
(2004). Histone deacetylase inhibitors: development as can-
cer therapy. Novartis Found Symp 259:269–281; discussion
281–288.
30. Wolffe AP and MA Matzke. (1999). Epigenetics: regulation
through repression. Science 286:481–486.
31. Cameron EE, KE Bachman, S Myohanen, JG Herman and SB
Baylin. (1999). Synergy of demethylation and histone dea-
cetylase inhibition in the re-expression of genes silenced in
cancer. Nat Genet 21:103–107.
32. Stein AB, TA Jones, TJ Herron, SR Patel, SM Day, et al.
(2011). Loss of H3K4 methylation destabilizes gene expres-
sion patterns and physiological functions in adult murine
cardiomyocytes. J Clin Invest 121:2641–2650.
33. Liu Z, T Li, Y Liu, Z Jia, Y Li, et al. (2009). WNT signaling
promotes Nkx2.5 expression and early cardiomyogenesis via
downregulation of Hdac1. Biochim Biophys Acta 1793:300–
311.
34. Zhang CL, TA McKinsey, S Chang, CL Antos, JA Hill, et al.
(2002). Class II histone deacetylases act as signal-responsive
repressors of cardiac hypertrophy. Cell 110:479–488.
35. Wamstad JA, JM Alexander, RM Truty, A Shrikumar, F Li, et
al. (2012). Dynamic and coordinated epigenetic regulation
of developmental transitions in the cardiac lineage. Cell
151:206–220.
36. Paige SL, S Thomas, CL Stoick-Cooper, H Wang, L Maves, et
al. (2012). A temporal chromatin signature in human em-
bryonic stem cells identifies regulators of cardiac develop-
ment. Cell 151:221–232.
37. Lieu DK, JD Fu, N Chiamvimonvat, KC Tung, GP McNer-
ney, et al. (2013). Mechanism-based facilitated maturation of
human pluripotent stem cell-derived cardiomyocytes. Circ
Arrhythm Electrophysiol 6:191–201.
38. Kaichi S, K Hasegawa, T Takaya, N Yokoo, T Mima, et al.
(2010). Cell line-dependent differentiation of induced plu-
ripotent stem cells into cardiomyocytes in mice. Cardiovasc
Res 88:314–323.
39. Kawamura T, K Ono, T Morimoto, H Wada, M Hirai, et al.
(2005). Acetylation of GATA-4 is involved in the differenti-
ation of embryonic stem cells into cardiac myocytes. J Biol
Chem 280:19682–19688.
40. Johannessen CU and SI Johannessen. (2003). Valproate: past,
present, and future. CNS Drug Rev 9:199–216.
41. Bradbury CA, FL Khanim, R Hayden, CM Bunce, DAWhite,
et al. (2005). Histone deacetylases in acute myeloid leukae-
mia show a distinctive pattern of expression that changes
selectively in response to deacetylase inhibitors. Leukemia
19:1751–1759.
42. Harikrishnan KN, TC Karagiannis, MZ Chow and A El-
Osta. (2008). Effect of valproic acid on radiation-induced
DNA damage in euchromatic and heterochromatic com-
partments. Cell Cycle 7:468–476.
43. Binah O, K Dolnikov, O Sadan, M Shilkrut, N Zeevi-Levin,
et al. (2007). Functional and developmental properties of
human embryonic stem cells-derived cardiomyocytes.
J Electrocardiol 40:S192–S196.
44. Liu J, DK Lieu, CW Siu, JD Fu, HF Tse, et al. (2009).
Facilitated maturation of Ca2 + handling properties of
human embryonic stem cell-derived cardiomyocytes by
calsequestrin expression. Am J Physiol Cell Physiol 297:
C152–C159.
45. Lieu DK, YC Chan, CP Lau, HF Tse, CW Siu, et al. (2008).
Overexpression of HCN-encoded pacemaker current si-
lences bioartificial pacemakers. Heart Rhythm 5:1310–1317.
46. Chan YC, CW Siu, YM Lau, CP Lau, RA Li, et al. (2009).
Synergistic effects of inward rectifier (I) and pacemaker (I)
currents on the induction of bioengineered cardiac auto-
maticity. J Cardiovasc Electrophysiol 20:1048–1054.
47. Backs J, K Song, S Bezprozvannaya, S Chang and EN Olson.
(2006). CaM kinase II selectively signals to histone deacety-
lase 4 during cardiomyocyte hypertrophy. J Clin Invest 116:
1853–1864.
48. Bush E, J Fielitz, L Melvin, M Martinez-Arnold, TA
McKinsey, et al. (2004). A small molecular activator of
cardiac hypertrophy uncovered in a chemical screen for
modifiers of the calcineurin signaling pathway. Proc Natl
Acad Sci U S A 101:2870–2875.
49. Chang S, TA McKinsey, CL Zhang, JA Richardson, JA Hill, et
al. (2004). Histone deacetylases 5 and 9 govern responsiveness
of the heart to a subset of stress signals and play redundant
roles in heart development. Mol Cell Biol 24:8467–8476.
50. Bradner JE, N West, ML Grachan, EF Greenberg, SJ Hag-
garty, et al. (2010). Chemical phylogenetics of histone dea-
cetylases. Nat Chem Biol 6:238–243.
51. Antos CL, TA McKinsey, M Dreitz, LM Hollingsworth, CL
Zhang, et al. (2003). Dose-dependent blockade to cardio-
myocyte hypertrophy by histone deacetylase inhibitors.
J Biol Chem 278:28930–28937.
52. Cardinale JP, S Sriramula, R Pariaut, A Guggilam, N
Mariappan, et al. (2010). HDAC inhibition attenuates in-
flammatory, hypertrophic, and hypertensive responses in
spontaneously hypertensive rats. Hypertension 56:437–444.
53. Cao DJ, ZV Wang, PK Battiprolu, N Jiang, CR Morales, et al.
(2011). Histone deacetylase (HDAC) inhibitors attenuate
cardiac hypertrophy by suppressing autophagy. Proc Natl
Acad Sci U S A 108:4123–4128.
54. Kong Y, P Tannous, G Lu, K Berenji, BA Rothermel, et al.
(2006). Suppression of class I and II histone deacetylases
blunts pressure-overload cardiac hypertrophy. Circulation
113:2579–2588.
55. Ahmad F, JG Seidman and CE Seidman. (2005). The genetic
basis for cardiac remodeling. Annu Rev Genomics Hum
Genet 6:185–216.
56. Moorman AF and VM Christoffels. (2003). Cardiac chamber
formation: development, genes, and evolution. Physiol Rev
83:1223–1267.
57. Brasacchio D, J Okabe, C Tikellis, A Balcerczyk, P George, et
al. (2009). Hyperglycemia induces a dynamic cooperativity
of histone methylase and demethylase enzymes associated
with gene-activating epigenetic marks that coexist on the
lysine tail. Diabetes 58:1229–1236.
Address correspondence to:
Prof. Ronald Li
Stem Cell and Regenerative Medicine Consortium (SCRMC)
The University of Hong Kong






Received for publication March 6, 2013
Accepted after revision May 8, 2013
Prepublished on Liebert Instant Online May 8, 2013
2690 CHOW ET AL.
